NCT06696963Completed
Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC
Impact of Time to Initiation of Postoperative Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy on the Prognosis of Locally Advanced Gastric Cancer: a Multi-center Study
Source: ClinicalTrials.gov · Last updated 20 Nov 2024
Brief summary (registry, in English)
he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers. This study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Informed consent was obtained from all patients and their legal guardians. All procedures were approved by the institutional review board.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 524 (actual)
- First submitted
- 17 Nov 2024
- Start date
- 15 Mar 2024
- Primary completion date
- 15 Apr 2024
- Lead sponsor
- Fujian Medical University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06696963
What you commit to
- Study type: Observational
- Participants enrolled: 524
- From 15 Mar 2024 to the primary completion date, 15 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (1) History of prior gastrectomy. (2) History of acute cardiovascular diseases (such as cerebral or coronary artery injuries) within the past three months. (3) Emergency surgery. (4) Did not undergo postoperative adjuvant chemotherapy. (5) Lack of specific information regarding chemotherapy regimens. (6) Loss to follow-up.
Who the study is looking for
- (1) Locally advanced gastric cancer with preoperative clinical staging of cT2-4NxM0 before neoadjuvant chemotherapy. (2) No history of other malignant tumors. (3) No evidence of distant metastasis or invasion of adjacent organs. (4) Underwent gastrectomy after receiving neoadjuvant chemotherapy.
Age in the registry: 18 years to 84 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Medical University Union Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.